Acquisition Empowers Approach to Complex Data Management

Biopharmaceutical software and consulting services company Cytel, a portfolio company has acquired MTEK Sciences expanding its real-world analytics (RWA) capabilities. MTEK specialises in methods such as machine learning models and Bayesian optimisation to derive clinical insights from large and complex real-world data (RWD).

“Complex RWD sets are now abundant in the healthcare sector, opening up a wealth of opportunity for pharmaceutical organisations of all sizes,” said Joshua Schultz, Chief Executive Officer at Cytel. “Advanced and more sophisticated analytical methods and decision-modelling techniques are needed to harness RWD and turn it into trustworthy evidence. At Cytel, we’re applying our long history of innovative statistical methods to RWD to generate cost-effective insights for our clients and the acquisition of MTEK is another avenue where we are amplifying this approach.”

Professor Edward Mills, Founding Partner and Director of MTEK, said, “Our experience has shown us that companies need to look beyond the confines of traditional analytical approaches if RWD is to positively transform clinical development. In working with Cytel, we're enhancing our combined ability to develop and deploy the novel solutions needed to confidently guide companies through this rapidly changing landscape.”

Professor Kristian Thorlund, Founding Partner and Director of MTEK Sciences, added, “Cytel and MTEK have a tightly aligned vision for the future of RWD applications. Combining our comprehensive statistical know-how means we can deliver greater innovation to a wider array of companies as they seek to enrich their drug development process with RWD.”